Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation

Core Viewpoint - Block & Leviton is investigating Aquestive Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price due to FDA deficiencies in its drug application [1][2]. Group 1: Company Overview - Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that the FDA identified deficiencies in its new drug application for Anaphylm, raising the risk of delayed approval [2]. - Block & Leviton is investigating the company's prior disclosures to determine if there were any violations of securities laws [4]. Group 2: Investor Eligibility - Any investor who purchased common stock of Aquestive Therapeutics and has experienced a decline in their investment may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Group 3: Legal Actions and Support - Block & Leviton is prepared to file an action to recover losses on behalf of investors who have lost money due to the company's disclosures [4]. - Investors who have non-public information about Aquestive Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many top institutional investors [7].